Medication Overuse Headache, Migraine
Conditions
Brief summary
This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache
Detailed description
Patients planned for randomization: 91 patients in the eptinezumab 100 mg group and 91 patients in the placebo group. The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Open-Label Period (12 weeks) and a Safety Follow-up Period (8 weeks). Patient will receive investigational medicinal product (IMP) at the Baseline Visit with either eptinezumab or placebo by IV infusion and at week 12 visit.
Interventions
DRUGPlacebo
Placebo - solution for infusion
DRUGEptinezumab
Eptinezumab - 100 mg, solution for infusion
Sponsors
H. Lundbeck A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The patient has a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 guidelines confirmed at the Screening Visit with a history of migraine onset of at least 12 months prior to the Screening Visit. * The patient has ≥8 migraine days per month for each month on average within the past 3 months prior to the Screening Visit. * The patient has a diagnosis of medication overuse headache (MOH) as defined by IHS ICHD-3 guidelines. * The patient has headache on ≥15 days/month for each month within the past 3 months prior to the Screening Visit. * The patient has regular overuse of one or more drugs that can be taken for acute and/or symptomatic treatment of headache, for \>3 months. * The patient has ≥15 to ≤26 headache days, of which ≥8 days were assessed as migraine days during the Screening Period, based on prospectively collected information in the eDiary. * The patient overuses drugs that can be taken for acute and/or symptomatic treatment of headache during the Screening Period, based on prospectively collected information in the eDiary. * The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days of the Screening Period. * The patient has had an onset of migraine at \<50 years of age
Exclusion criteria
* The patient has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway. * The patient has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome). * The patient has a diagnosis of acute or active temporomandibular disorder. * The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration). * Patients with a lifetime history of psychosis, bipolar mania, or dementia are excluded. Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded. * The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). Other in- and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the number of monthly migraine days (MMDs) | Weeks 1-12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response: ≥50% reduction from baseline in MMDs | Weeks 1-12 | — |
| Migraine rate on the day after dosing | At Day 1 | — |
| Response: ≥75% reduction from baseline in MMDs | Weeks 1-4 | — |
| Change from baseline in the number of monthly headache days (MHDs) | Weeks 1-12 | — |
| Response: ≥75% reduction from baseline in MHDs | Weeks 1-12 | — |
| Change from baseline in the number of MHDs with use of acute medication | Weeks 1-12 | — |
| Change from baseline in rate of migraines with severe pain intensity | Weeks 1-12 | — |
| Change from baseline in MMDs with use of acute medication | Weeks 1-12 | — |
| Patient Global Impression of Change (PGIC) score | At Week 12 | — |
| Most Bothersome Symptom (MBS) (score as measured relative to Screening) | At Week 12 | — |
| Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score | Baseline to Week 12 | — |
| Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) | Baseline to Week 12 | — |
| Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score | Baseline to Week 12 | — |
| Health Care Resources Utilization (HCRU) | Baseline to Week 12 | Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays. |
| Change from baseline to Week 12 in the Work Productivity and Activity impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment) | Baseline to Week 12 | — |
| Change from baseline in rate of headaches with severe pain intensity | Weeks 1-12 | — |
Countries
China, Georgia, South Korea, Spain, Taiwan
Outcome results
None listed